Controlled, prospective, open-label trial with a total duration of 2 weeks to assess theclearance of inflammatory interleukins by different membranes in haemodialysis patientswith COVID-19.
Controlled, prospective, open-label trial with a total duration of 2 weeks to assess the
clearance of inflammatory interleukins by different membranes in haemodialysis patients
with COVID-19.
Patients will be dialysed according to the usual dialysis schedule of three weekly
sessions. The study has a duration of 8 days in order to include 4 haemodialysis
sessions. The first and third haemodialysis sessions will be dialysed with PS membrane
and the second and fourth sessions with PMMA membrane, both dialysers with a surface area
of 1.8 m2.
Device: PS membrane versus PMMA membrane,
Patients will be dialysed according to the usual dialysis schedule of three weekly
sessions. The study has a duration of 8 days in order to include 4 haemodialysis
sessions. The first and third haemodialysis sessions will be dialysed with PS membrane
and the second and fourth sessions with PMMA membrane, both dialysers with a surface area
of 1.8 m2.
Inclusion Criteria:
- Age ≥18 years .
- Patient on chronic haemodialysis admitted to the hospital with a diagnosis of
infection by COVID-19.
- Signature of informed consent or legal representative.
- Estimated duration of admission greater than 8 days (4 haemodialysis sessions).
- Patient with haemodynamic stability, understood as systolic blood pressure ≥ 100
mmHg.
Exclusion Criteria:
- Refusal to sign the consent form.
- Patients who for clinical reasons are unable to follow a regular dialysis schedule
of three sessions per week.
- Allergy (documented or suspected) to either of the two membranes involved in the
study.
- Patient with haemodynamic instability (Mean arterial pressure < 100 mmHg).
Hospital Clínico Universitario de Valencia
Valencia, Valencian Community, Spain
Not Provided